SCHEMBL23327655

SCHEMBL23327655

O=C(NCc1cccnc1N1CCOCC1)c1cnnc(-c2cccc(Cl)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 7/20 0.68
SCN2A Q99250 6/20 0.68
KDM1A O60341 2/20 0.44
HDAC1 Q13547 2/20 0.44
MAPK8 P45983 3/20 0.42
SCN9A Q15858 1/20 0.42
STK4 Q13043 1/20 0.42
STK3 Q13188 1/20 0.42
LRRK2 Q5S007 1/20 0.42
POLB P06746 1/20 0.41
P2RX7 Q99572 1/20 0.41
MAPK14 Q16539 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327910 0.91 SCN10A (0.75) SCN10ASCN2AKDM1AHDAC1MAPK8
SCHEMBL23327907 0.89 SCN10A (0.66) SCN10ASCN2AKDM1AHDAC1P2RX7
SCHEMBL23344751 0.86 SCN10A (0.62) SCN10ASCN2AKDM1AHDAC1
SCHEMBL30882106 0.86 SCN10A (0.62) SCN10ASCN2AMAPK8
SCHEMBL23327962 0.86 SCN10A (0.62) SCN10ASCN2AMAPK8
SCHEMBL30882123 0.86 SCN10A (0.68) SCN10ASCN2AMAPK8P2RX7
SCHEMBL23328017 0.86 SCN10A (0.68) SCN10ASCN2AMAPK8P2RX7
SCHEMBL23327999 0.85 SCN10A (0.61) SCN10ASCN2AKDM1AHDAC1POLB
SCHEMBL23344685 0.84 SCN10A (0.60) SCN10ASCN2AKDM1AHDAC1MAPK14
SCHEMBL23327989 0.84 SCN10A (0.60) SCN10ASCN2AKDM1AHDAC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP claimed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US claimed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN claimed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US claimed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN claimed
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
CN-112689629-B For inhibiting Nav1.8 Pyridazine Compounds 利伯研究所公司 2024-04-23 CN disclosed
EP-3820860-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 Lieber Institute, Inc. (US) 2021-05-19 EP disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
CN-112689629-A For inhibiting Nav1.8 pyridazine Compounds 利伯研究所公司 2021-04-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885KDM1A 3241/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A SCN10A 8/4885SCN2A 3/4885KDM1A 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.